1ROSSELLA E,MATI'A K K. Women's voices in the menopause: results from an international survey on vaginal atrophy[J]. Maturitas ,2010 ,67 (3) :233-238.
2IRWIN G, BRIAN D, NOEL N ,et al. Multidisciplinary overviem of vaginal atrophy and associtaed genitourinary symptoms in postmenopausal women [J]. Sexual Med, 2013,1(2) :44-53.
3GOLDSTEIN I. Recognizing and treating urogenital atrophy in postmenopausal women[J].J Women's Health,2010,19 (3) :425 -432.
4PINKERTO N J. Vaginal impact of menopause-related estrogen deficiency [J]. OBG Management ,2010 ,22( 11) :2-7.
5MAC B, RHODES D J, SHUSTER L T. Vulvovaginal atrophy[J]. Mayo Clin Proc ,2010 ,85 (1) :87 -94.
6STURDEE D W ,PANAY N. Recommendations for the management of postmenopausal vaginal atrophy [J]. Climacteric ,2010,13 (6) :509--:522.
7CHRISTINE E S, IIKA B P , STEFAN A, et al. The effect of genital and lower urinary tract symptoms on steroid receptor expression in women with genital prolapse [J]. Int Urogyneco J ,2011 ,22( 6) : 705-712.
8RUBEN H, JEAN M, GREGOR R, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness [J]. PloS One, 2011 , 6 (11) :1-8.
9EWIES A A, ALFHAILY F. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick [J]. Climacteric, 2010,13 (5) : 405- 418.
10CODY J D, RICHARDSON K, MOEHRER B, et al. Oestro- gen therapy for urinary incontinence in postmenopausal women [J] . Cochrane Database Syst Rev, 2009 : CDOO 1405.
2[1]Manonai J,Theppisai U,Chittaeharoen A.Effect and safety of 17beta-estradiol vaginal tablet in postmenopausal women with urogenital symptoms[J]J Med Assoc Thai,2001,84(7):1015.
3[2]Manorial J,Theppisai U,Suthutvoravut s,et al.The effect of eatradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal wolnen:a comparative study[J]J Obstet Gyrmecol Res,2001,27(5):255.
4[3]Chanrachakul B,Herabutya Y,Punyavachira P.Randimized compariso of glyceryl trinitrate and prostaglandin E2 for cervicav ripening at term.[J].Obstet Gynecol,2000,9(4):549.
5[4]Petersen E.Eiko,Magnani Paola.Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis:a randomized,double blind,placebo-controlled study[J].Eur J Obstet Gynecol Reprod Biol,2004,117(1):70.
6[5]Khoury AN,Zhou QP,Gorenberg DM,et al.A comparison of intermittent vaginal administration of two different doses of misoprestol suppositories with continuous dinoprestone for cervical ripening and labor induction[J].J Matern Fetal Med,2001,lo(3):186.
7[6]Nova'k A,Lnge C,Ebetz L,et al.The combined contraceptive vaginal ring,NuvaRing:an international study of user acceptability[J].Contraception,2003,67:187.
8[7]Mulders TM,Dieben TO.Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition[J].Fertil Steril,2001,75(5):865.
9[8]Boumen FJ,Apter D,Mulders TM,et al.Efficacy,tolerability and acceptability of a novel contraceptive vagillal ring releasing etonogestrel and ethinyl oes-tradiol[J].Hum Reprod,2001,16(3):469.
10[9]Saltzman WM,Sherwood JK,Adams DR,et al.Long-term vaginal antibody delivery:.defivery systems and biodistribution[J].Biotechnol Bioeng,2000,67(3):253.
